Bu retrospektif çalışma sonucunda nondipper hipertansif bireylerin dipper hipertansif ve normotansif bireylere göre daha yüksek ortalama NLO, PLO ve MPV değerlerine sahip olduğunu ve MPV nin NDHT için bağımsız prediktif değeri olduğu bulunmuştur. Ayrıca NDHT grubu daha yüksek IVS değerlerine sahiptir. NDHT hastalarının artmış kardiyovasküler olay riski taşıdığı düşünüldüğünde, bu hasta grubunda ortalama HT süresi, IVS kalınlığı ve NLO, PLO ve MPV değerlerinindaha yüksek bulunması bu parametrelerin kötü kardiyovasküler sonlanım ile ilişkili olabileceklerini desteklemektedir.
7.KAYNAKLAR
1. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet1978;1:795-7.
2. Campanini B. The World Health Report: Reducing Risks, Promoting Healthy Life. Geneva, World Health Organization, 2002
3. 2003 World Health Organization (WHO)/ İnternational Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension 2003,21:1983-1992
4. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996; 27: 1214–1218.
5- Staessen JA, Thijs L, Fagard R, O’Brien ET, Clement D, de Leeuw PW, ManciaG, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascularrisk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999;282: 539–546. OS.
6-Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA,Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P,O’Brien E. Prognostic value of ambulatory blood pressure recordings in patientswith treated hypertension. New Engl J Med 2003;348:2407–2415. OS.
7-Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G.Prognostic value of ambulatory and home blood pressure compared with Office blood pressure in the general population: follow-up results from the PAMELA study. Circulation 2005;111:1777–1783. OS.
8- Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O’Brien E. Superiority of ambulatory over clinicblood pressure measurement in predicting mortality. Hypertension2005;46:156–161. OS.
9- Seo WS, Oh HS. The circadian rhythms of blood pressure and heart rate in the hypertensivesubjects: dippers and non-dippers. Yonsei Med J 2002;43:320-8.
10-Fujii T, Uzu T, Nishimura M, Takeji M, Kuroda S, Nakamura S, et al. Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Am J Kidney Dis 1999; 33:29-35
11 Ersoylu ZD, Tuğcu A ve ark. Dipper ve nondipper hipertansiyonlu hastalarda sol ventrikül hipertrofisi, diyastolik fonksiyon bozukluğu ve aritmi sıklığının karşılaştırılması. Türk Kardiyol. Dern. Arş. 2008; 36:310-317
12- Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertensionMurat Sunbul, Fethullah Gerin, Erdal Durmus, Tarik
Kivrak, Ibrahim Sari, Kursat Tigen, and Altug Cincin Clin Exp Hypertens, Early Online: 1–5 2013 Informa Healthcare USA, Inc. DOI: 10.3109/10641963.2013.804547
13- Mean platelet volume in patients with dipper and non-dipper hypertensionSerkan Ordu, Hakan Ozhan, Onur Çağlar, Recai Alemdar, Cengiz Basar,Mehmet Yazıcı&İsmail ErdenDuzce University, Düzce Medical School, Department of Cardiology 81620, Konuralp Düzce, TurkeyBlood Pressure. 2010; 19: 26–30
14 Evaluation of biochemical, hematological, and thyroid function parameters in nondipper and dipper hypertensive patientsIbrahim Akpinar, Nurcan Basar, Nihat Sen, Halil Lutfu KisacikWien Klin Wochenschr (2012) 124:439–443 DOI 10.1007/s00508-012-0196- Wiener klinische Wochenschrift The Central European Journal of Medicine
15-Comroe JH. Exploring the Heart: Discoveries in Heart Disease and High Blood Pressure, New York, Norton, 1983.
16-Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: A cooperative study. JAMA 1977; 237: 255-261
17-The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980; 140:1280-1285
18. 2014 Evidence-Based Guideline for the Managementof High Blood Pressure in Adults
Report From the Panel Members Appointedto the Eighth Joint National Committee (JNC 8). JAMA. doi:10.1001/jama.2013.284427Published online December 18, 2013.
19.Guidelines Subcommittee of The World Health Organization. World HealthOrganization-International Society of Hypertension guidelines for themanagement of hypertension. J Hypertens 1999; 17: 151-183.
20-2013 ESH/ESC Guidelines for themanagementof arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) European Heart Journal (2013) 34, 2159–2219
21-National High Blood Pressure Education Program working group report on primaryprevention of hypertension. Arch _ntern Med 1993:153-186.
22.Lewington S, Clarke R, Collin SR, et al. Age-specific relevance of usual blood pressure tovascular mortality: A meta analysis of individual data for one million adults in 61 prospectivestudies. Prospective studies collaboration Lancet 2002;360:1903-13.
23-Akıllı, A. Tanı, Sınıflama, Klinik Yaklaşım, Tetkikler. Hipertansiyon. İlsan- İltaşİlaç Firması, İzmir.1998; s1-23.
24-Özmen M. Hipertansiyon, kişilik yapısı ve stres. Hipokrat Dergisi 2002; 11:339- 342.
25.Davies SJ, Ghahramani P, Jackson PR, Hippisley-Cox J, Yeo WW, RamsayLE. Panic disorder, anxiety and depression in resistant hypertension--a casecontrolstudy. J Hypertens 1997; 15: 1077-1082.
26-NICE clinical guideline 127 Hypertension: clinical management of primary hypertension in adults Issue date: August 2011
27- Lewington S, Clarke R, Qizilbash N ve ark. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 287:1003-1010
28- M. Ezzati , A. D Lopez, A. Rodgers, S. V. Hoorn, C. JL. Murray, Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 9343, 1347–1360
29- P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, J. He. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217– 223
30-Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-1249
31-Onat A, Karabulut A, Yazıcı M, Can G, Sansoy V. Türk yetişkinlerde hiperkolesterolemi ve hipertansiyon birlikteliği: sıklığına ve kardiyovasküler riski öngördürmesine ilişkin TEKHARF çalışması verileri. Türk KardiyolojiDerneği Arşivi 2004; 32: 533-41.
32-Altun B, Arici M, Nergizoglu G, et al. For the turkish society of hypertension and renaldiseases. Prevalance, awareness, treatment and control of hypertension in Turkey (thePatenT study) in 2003. J Hypertens 2005; 23:1817-23.
33- Arici M, Turgan C, Altun B, Sindel S, Erbay B, Derici U, Karatan O, Erdem Y,Hasanoglu E, Caglar S. Hypertension incidence in Turkey (HinT): a population- based study; Turkish Society of Hypertension and Renal Diseases. J Hypertens. 2010 Feb;28: 240-244.
34-W.B.Kannel.Blood Pressure as a Cardiovascular Risk Factor Prevention and Treatment. AMA. 1996;275:1571-1576.
35-Ramzi S. Cotran, Stanley L. Robbins, Vinay Kumar. Temel Patoloji Basic Pathology. Nobel Tıp Kitabevleri.7. Baskı 2002; s:294-298
36-Carretero O, Oparil S. Essential hypertension part I: Definition and etiology. Circulation. 2000; 101: 329–335
37-Onusko E. Diagnosing Secondary Hypertension. Am. Fam. Physician. 2003 Jan 1;67: 67-74
38- Battegay E. J, Lip G. Y. H, Bakris G. L, Çeviren: Ö.Kozan Hipertansiyon temelleri ve uygulama I. Baskı 2009, Bölüm 2, 15-22
39- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7),. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. JAMA. 2003 May 21; 289: 25ö60-72. Epub 2003 May 14
40-Kaplan NM: Clinical Hypertension.7th ed. Baltimore, Willams&Wilkins,1998.
41-.J. Mayet, A.Hughes. Cardiac and vascular pathophysiology in hypertension. Heart. 2003 September; 89: 1104–1109.
42- Harrap SB. Blood pressure Genetics.In: oparil S, Weber MA, eds. Hypertension: Companion to Brenner and Rector’s The kidney. Philadelphia, Post anulus: WB Saunders; 1999:ch.4
43-Iliodau A, Lichenstein P, Morgenstern R, et al. Repeated blood pressure measurments in a sample of Swedish twins: Heritabilities and associatons with
polymorphisms in the reninanjiotensin–aldosterone system. J Hypertens 2002;20:1543-50.
44-Luft FC: Molecular genetics of human hypertension. J Hypertension 1998;16: 1871.
45-Babalık E. Hipertansiyon patofizyolojisi. Klinik Gelişim 2005;18: 25-32.
46-Law CM, shiell AW ve ark. Fetal, Infant, and Childhood Growth and Adult Blood Pressure A Longitudinal Study From Birth to 22 Years of Age. Circulation. 2002;105:1088-1092.
47-Brenner MB, Chertow GM. Congenital oligonephropathy and the ethiology of adult hypertension and progressive renal injury. Am J Kidney Disease 1994;23:171- 5.
48-B. T. Alexander. Fetal programming of hypertension. AJP- Regu Physiol January 2006; 290 no. 1 R1-R10
49-Julius S, Schork MA. Predictors of hypertension. Ann N Y Acad Sci 1978;304: 38-58.
50-Julius S, Valentini M. Continuing on J. P. Henry's path; studies of physiologyand pathophysiology of cardiopulmonary receptors in humans. Acta PhysiolScand Suppl.1997; 640: 122-4.
51- Braunwauld’s Heart disease international 8.th edition 2008; 40:1027-1047
52-Weber MA. Angiotensin 2 receptor antagonist in the treatment ofhypertension. Cardiol Rev 1997; 5: 72-80.
53- Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH.On the renal basis for essential hypertension: nephron heterogeneity withdiscordant rennin secretion and sodium excretion causing a hypertensivevasoconstriction- volume relationship. J Hypertens.1988; 6: 763-77.
54-Johnson RJ, Feig DI et al. Pathogenesis of essential hypertension: historical paradigms and modern insights J Hyperten. 2008 March; 26: 381-391.
55- Barba G, Cappuccio FP, Russo L, Stinga F, Iacone R, Strazzullo P. . Renal function and blood pressure response to dietary salt restriction in normotensive men. Hypertension 1996 May;27:1160-4.
56- Geleijnse JM, Witteman JCM, Den Breeijen JH, Hofman A, de Jong PTVM, Pols HAP, Grobbee DE. Dietary electrolyte and intake and blood pressure in older subjects: the Rotterdam Study. J Hypertens. 1996;14:737–741.
57- Sasaki S, Zhang XH, Kesteloot H. Dietary sodium, potassium, saturated fat, alcohol, and stroke mortality. Stroke 1995;26:783-9
58- Hall JE, Brands MW, Shek EW. Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens. 1996 Oct;10:633-9.
59-Laragh JH. The renin system and four lines fo hypertension research. Nephron heterogeneity, the calcium connection, the prorenin vasodilator limb, and plasma renin and heart attack. Hypertension. 1992 Sep;20: 267-79.
60-Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol and triglyceride (Cochrane Review). Am J Hypertens 2012;25:1–15.
61-He FJ, MacGregor GA. How far should salt intake be reduced? Hypertension 2003; 42:1093–1099.
62- Sacks FM, Laura MD, Svetkey P, William M. Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. N Engl J Med 2001; 344:3-10January 4, 2001
63- Erdem Y, Arici M, Altun B, Turgan C, Sindel S, Erbay B, Derici U, Karatan O, Hasanoglu E, Caglar S. The relationship between hypertension and salt intake in Turkish population: SALTURK study. Blood Press. 2010 Oct;19:313-8.
64-.Obrist PI, Light KC, James SA, Strogatz DS. Cardiovascular responses to stress: I. Measures of myocardial response and relationship to high resting systolic pressure and parental hypertension. Psychophysiology 1987; 24: 65- 78.
65-.Calhoun DA, Muntinga ML. Race, family history of hypertension, and sympathetic response to cold pressor testing. Blood Press.1997; 6: 209-13.
66-Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S. Insulin Resistance, Hyperinsulinemia, and Blood Pressure Role of Age and Obesity. Hypertension. 1997; 30: 1144-1149
67-Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension. 1992; 20:38-45
68-Baron AD, Brechtel-Hook G ,Johnson A ,Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension. 1993 Feb;21:129-35.
69- Hausberg M, Hoffman RP, Somers VK, Sinkey CA, Mark AL, Anderson EA. Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension. 1997 Mar;29:700-5.
70-Stehouwer CD, Lambert J, Donker AJM, Van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55- 68.
71-Bakris GL, Walsh MF, Sowers JR. Endothelium/ mesangium interactions: Role of insulin-like growth factors. In:Sowers JR, ed. Endocrinology of the Vasculature. Totowa NJ: Huma Pres;1996; 341.
72-Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994; 123: 647- 52.
73- Puddu P, Puddu GM, Zaca F, Muscari A. Endothelial dysfunction in hypertension.Acta Cardiol. 2000 Aug;55: 221-32.
74-Turkiye Klinikleri J Int Med Sci 2005; 1(33): 6-11
75-Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, Levy P, Riha R,Bassetti C, Narkiewicz K, Mancia G, McNicholas WT. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (Co-operation in Scientificand Technological research) ACTION B26 on obstructive sleep apnea.J Hypertens 2012;30:633–646.
76-Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet 1987;1: 647– 651.
77-Grassi G, Seravalle G, Calhoun DA, Bolla GB, Giannattasio C, Marabini M, Del BoA, Mancia G. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation 1994;90:248–253.
78-Mancia G, Groppelli A, Di Rienzo M, Castiglioni P, Parati G. Smoking impairs baroreflex sensitivity in humans. Am J Physiol 1997;273:H1555–1560.
79-Mancia G, Groppelli A, Di Rienzo M, Castiglioni P, Parati G. Smoking impairs baroreflex sensitivity in humans. Am J Physiol 1997;273:H1555–1560.
80-Bang LE, Buttenschon L, Kristensen KS, Svendsen TL. Do we undertreat hypertensivesmokers? A comparison between smoking and non-smoking hypertensives. Blood Press Monit 2000;5:271–274.
81-Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. J Hypertens 1992;10:495–499.
82- Mann SJ, James GD,Wang RS, Pickering TG. Elevation of ambulatory systolic bloodpressure in hypertensive smokers. A case-control study. JAMA 1991;265: 2226–2228.
83-Guidelines for the evaluation and management of heart failure: Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995; 92: 2764
84- MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
85-Multiple Risk Factor Intervention Trial Group. Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results. JAMA 1982; 248: 1465-77
86- Levy D, Wilson PW, Anderson K ve ark: Stratifying the patient at risk from coronary disease: New insights from the Framingham study. Am Heart J 1990; 119: 712-7
87- Kannel W B, Sorlie P, Castelli W P ve ark: Blood pressure and survival after myocardial infarction: The Framingham study. Am J Cardiol 1980; 45: 326-30
88-Kannel WB: Vital epidemiologic clues in heart failure. J Clin Epidemiol 2000, 53:229-235 .
89-Levy D, Larson M, Vasan R. The progression from hypertension to congestiveheart failure. JAMA, 1996; 275(20).
90-Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996; 156:1789-96.
91- Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC,Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A,Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 2369–2429.
92- Grundvold I, Skretteberg PT, Liestol K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension 2012;59: 198–204.
93- Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Vardas P, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011;106:1012–1019.
94-Levy D, Salomon M, Kanel WB, et al. Prognostic implications of baseline electrocar diographic features and their serial changes in subjects with left ventricular hypertrophy, circulation. 1994; 90: 1786-1793.
95-Pedrinelli R, Microalbüminuria in Hypertension. Nephron 1996; 73: 499-505.
96-Pantremoli R, Nicolella C, Viazzi F, et al. Microalbuminüri’a is an early marker of forget organ damage in essential hypertension. Am J. Hypertens. 1998; 11: 430- 438.
97-Gerstein HC, Mann JF, Yusuf S, et al. HOPE study investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non – diabetic individuals. JAMA, 2001; 286: 421-426.
98-Hillege HL, Fidler V, de Jang PE, et al. Prevention of Renal, vascular end Stage Disease (PREVENO) Study Group Urinary albumin exaretion predicts cardiovascular and non – cardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
99-Jensen JC, Feldt Rasmussen B, Brch Johnsen k. Arterial Hypertension Microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898- 903.
100- Yüksel A, Arınsoy T. Hipertansiyonun akut ve kronik renal etkileri. Turkiye Klinikleri J Int Med Sci 2005, 1:65-69.
101- Sezer S, Külah E, Özdemir FN. Hipertansiyonun Renal Komplikasyonlar Ve Böbrek Hastalığının Progresyonundaki Rolü. Journal of the Turkish Society of Nephrology 2003 ;12: 67-73
102-Jenette JC, Olson JL, Schwartz MM, Silva FG (eds). Heptinstall's pathology of the kidney (5th ed) Philadelphia. Lippincott-Raven 1998;2:943-1002.
103- Bats ML, Hofman A, Grobbee DE, et al. Comman carotid intima-media thickness and risk of stoke and mycordial infarotion: The Rotterdam Study circulation 1997; 96: 1432-1437.
104-.Laurent S, Gautier I, Benetos A, et al. Aortic stiffness is on independent predictorof all-cause and cardiovascular mortality in hypertensive patients. Hypertension2001; 37: 1236-1241.
105- Forigna HH, Boersma E, El hendy A, et al. The long term prognostic value of theresting and post exercise ancle-brochial index. Arch. Đntern. Med. 2006; 166: 529-535.
106- McKenna M, Wolfson S, Kuller L. The ratio of ancle and arm orterial pressure ason independet predictor of mortality. Atherosclerosis, 1991; 87: 119-128.
107-Meszaros I, Morocz J, Szlavi J, et al. Epidemiology and clinicopathology ofaortic dissection. Chest 2000; 117: 1271- 8.
108- Sacco Rl. Risk factors and outcomes for ischemic stroke. Neurology 1995;45:S10.
109- Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827.
110- Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991 Jun 26;265:3255-64.
111-MacMahon S, Tzourio C, Rodgers A, et al. for the PROGRESS Colloborative Group. Randomised trial of a perindopril- based blood pressure–lowering regimen among 6,105 individulas with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-41.
112.Büyüköztürk K. Ulusal Hipertansiyon Tedavi ve Takip. Kılavuzu. Türk Kardiyoloji Dernegi, İstanbul 1999
113.Wagener HP, Clay GE, Gipner JF: Clasification of retinal lesions in the presence of vascular hypertension. Trans Am Ophtalmol Soc 1947; 43: 57-73
114.D’Agostino RBS, Sullivan LM, Wilson P, et al. Validation of the framingham Coronary heart disease prediction scares: results of a multiple ethnic groups investigation, JAMA 2001; 286: 180-187.
115.Conroy RM, Menotti A, Graham IM, et al. Estimation of ten year risk of total cardiovascular disease in Europe: the SCORE Project. Eur. Heart J. 2003; 24: 987- 1003.
116.Sever PS, Dahlof B, Poulter NR ve ark. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): A multicenter randomised controlled trial. 2003 Lancet 361:1149
117. GaborieauV, Delarche N, Gosse P. Ambulatory blood pressure monitoring vs. self measurement of blood pressure at home: correlation with target organ damage. J Hypertens 2008;26:1919–1927.
118 Bliziotis IA, Destounis A, Stergiou GS. Home vs. ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens 2012;30:1289–1299.
119. Stergiou GS, Siontis KC, Ioannidis JP. Home blood pressure as a cardiovascular outcome predictor: it’s time to take this method seriously. Hypertension 2010;55: 1301–1303.
120. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 2012;30:449–456.
121. Mancia G, Sega R, Bravi C et al: Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995; 12: 1377-90
122.Ohkuba T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals withand without high 24-4 blood pressure: The ohasoma study J Hypertens 2002; 20: 2183-2189.
123.Verdecchia P, Schilacci G, Borgiani C, et al. Altered circadion blood pressure profile and prognosis. Blood pressure monitoring. 1997; 2:347-352.
124.Pirerdomenico S, Bucci A, Mezzetti A, et al. Circadion blood pressure changes and myocardial ischemia in hypertensive patients with coronary ortery disease. J. Am Coll Cardiology. 1998; 31: 1627-1634.
125.Koriko K, Pickering TG, Matsuo T, et al. Stroke prognosis and abnormal nacturnal blood pressure falls in older hypertensives, Hypertension 2001; 38: 852- 857.
126. Parati G, De Leeuw P, İllyes M, et al. Blood pressure measurement in research. Blood Press Monit. 2002;7:83-87.
127.Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 2006;47:846–853.
128.Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens 2007;25:2193–219
129.Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 2011;24:52–58.
130. Franklin SS, Thijs L, Hansen TW, Li Y, Boggia J, Kikuya M, Bjorklund- Bodegard K, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y,Wang J, Ibsen H, O’Brien E, Staessen JA. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012;59:564–571.
131. Kanbay M, Turgut F, Uyar ME, Akcay A, Covic A. Causes and mechanisms of nondipping hypertension. Clin Exp Hypertens. 2008 Oct;30:585-97.
132. Horne BD, Anderson JL, John JM et al. Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005;45(10):1638 –1643.
133. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008;102(6):653– 657.
134 Uthamalingam S, Patvardhan EA., Subramanian S et al. Utility of the Neutrophil to Lymphocyte Ratio in PredictingLong-Term Outcomes in Acute Decompensated Heart Failure. Am J Cardiol 2011;107(3):433-8.